secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001140361-26-012346
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys reports 2025 revenue up 40.8% to $2.3M; net loss $18.6M; cash into Q3 2026
--------------------------------------------------------------------------------

- Revenue increased 40.8% to $2,293,313 in 2025 from $1,629,108 in 2024, driven by FemBloc sales.
- Net loss was $18,627,887 ($0.47 per share) vs $18,816,628 ($0.85 per share) in 2024; EPS improved on share count increase.
- Cash and cash equivalents $9.3M as of Dec 31, 2025; expects to fund operations into Q3 2026.
- Initiated patient enrollment in FINALE pivotal trial for FemBloc; received MDSAP certification.
- Completed $12M financing in late 2025; appointed Kenneth D. Eichenbaum to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036126012346/0001140361-26-012346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036126012346/ef20069346_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-012346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer